Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Odevixibat Study in Japanese PFIC Patients
jRCT2061230022Phase 3Completed
- Sponsor
- Jadeite Medicines
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC), sponsored by Jadeite Medicines. Primary endpoints: Fasting serum bile acid response at Week 24, Pruritus response over 24-week Dose Adjustment Period and 2 more. Started Sep 2023; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on jRCT2061230022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230022.